1-1 of 1
SHUYING LI
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)

LINONG JI, WEIHONG SONG, HUI FANG, WEI LI, JIANLIN GENG, YAN CHENG XU, YANGANG WANG, LIAN GUO, HANQING CAI, TAO YANG, HONG-MEI LI, GANGYI YANG, QIFU LI, SR., KUANZHI LIU, SHUYING LI, YANJUN LIU, FUYAN SHI, XIN SHENG LI, XIN GAO, QIUHE JI, HAOMING TIAN, QING SU, ZHIGUANG ZHOU, WENBO WANG, ZUNHAI ZHOU, XUEJUN LI, YAN CHENG XU, ZHIQIANG NING, XIANPING LU, WEIPING JIA
Journal: Diabetes
Diabetes 2019;68(Supplement_1):17-OR
https://doi.org/10.2337/db19-17-OR
Published: 01 June 2019
View article titled, 17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)